Chris Viehbacher

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Chris Viehbacher (born 1960) is a German-Canadian businessman.[1][2][3][4] He served as the Chief Executive Officer of Sanofi and Chairman of Genzyme until 29 October 2014.[2][3][4] Viehbacher is currently Managing Partner of Gurnet Point Capital, a healthcare venture capital and private equity fund backed by Ernesto Bertarelli and his family.[5][6]

Early life[edit]

Chris Viehbacher was born on March 26, 1960.[4] He graduated from Queen's University in Kingston, Ontario, Canada.[1][3][4] He is a certified public accountant, and he speaks French, German and English.[1][3][4]


Viehbacher started his career at PriceWaterhouseCoopers.[1][3][4] In 1988, he joined GlaxoSmithKline, where he worked for the next twenty years, including in France for ten years.[1][3] Until October 29, 2014, he served as CEO of Sanofi and Chairman of Genzyme.[3][4] Viehbacher has been Managing Partner of US-based healthcare investment fund Gurnet Point Capital since 2015.[7]

Viehbacher was Chairman of the Pharmaceutical Research and Manufacturers of America from December 2010 to April 2012.[2][3][4] He has been Chair of the CEO Roundtable on Cancer since February 2011.[3][4] He is a member of The Business Roundtable and the International Business Council.[3] He sits on the Board of Directors of Research America and the Burroughs Wellcome Fund.[2] He will serve as President of the European Federation of Pharmaceutical Industries and Associations from June 2013 onwards.[2][3]

In 2003, Viehbacher became a Knight in the Legion of Honour.[3] In 2012, he received the Pasteur Foundation Award.[3] He sits on the Board of Visitors of the Fuqua School of Business at Duke University.[3]

Personal life[edit]

Viehbacher is married and has three children, including a son.[4]


  1. ^ a b c d e Christopher Viehbacher: Executive Profile & Biography - Businessweek
  2. ^ a b c d e Christopher Viehbacher - Forbes
  3. ^ a b c d e f g h i j k l m n "Archived copy". Archived from the original on October 29, 2014. Retrieved October 29, 2014.CS1 maint: Archived copy as title (link) Sanofi
  4. ^ a b c d e f g h i j Christopher A. Viehbacher | CEO Roundtable on Cancer
  5. ^ "Ex-Sanofi CEO talks about his new $2 billion investment fund". Retrieved 2017-09-13.
  6. ^ "Gurnet Point Capital nears deal to acquire drugmaker Innocoll: sources". Reuters. April 4, 2017. Retrieved 2017-09-13.
  7. ^ "Subscribe to read". Financial Times. Retrieved 2017-11-17.
Business positions
Preceded by
Gérard Le Fur
CEO of Sanofi
Succeeded by
Olivier Brandicourt